Pretreatment CA19‐9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy
Journal of Surgical Oncology · 2026
DOI: 10.1002/jso.70179 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Surgical Oncology, 2026. Verfasst von Anthony Gebran und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, CA-19-9 Antigen, Neoadjuvant Therapy, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background and Objectives Pancreatic ductal adenocarcinoma (PDAC) is characterized by limited survival rates, yet patients who achieve optimal CA19‐9 response to neoadjuvant therapy (NAT) exhibit improved survival. This study examines the association between initial CA19‐9 levels and survival in PDAC patients who achieved CA19‐9 normalization with systemic chemotherapy.
Methods
A retrospective, multi‐institutional analysis of patients with resectable/borderline‐resectable PDAC, who underwent NAT and curative‐intent pancreatectomy at the University of Pittsburgh Medical Center, University of Texas Southwestern Medical Center, NorthShore University, and West Virginia University To contexualize thi between 2010 and 2022, was performed. CA19‐9 secretors (> 37 U/mL, with total bilirubin < 2) at diagnosis, with optimal response to NAT (normalization and > 50% drop in CA19‐9) were included. A cutoff for pre‐NAT CA19‐9 of 400 U/mL was determined to maximize sensitivity and specificity for survival benefit, and the cohort was accordingly divided into two groups. Kaplan–Meier and Cox proportional‐hazards models were used for univariate and multivariable analyses.
Results
A total of 134 patients were included, 32 (23.9%) had a pre‐NAT CA19‐9 ≥ 400U/mL. DFS and OS were considerably higher among patients with pre‐NAT CA19‐9 < 400U/mL (median(95%CI) in months, DFS:19.8(16.0,33.4) versus 7.8(5.0,13.0); OS:49.0(34.5,70.7) versus 23.1(13.8,50.9)). On multivariable analysis, pre‐NAT CA19‐9 ≥ 400 U/mL was significantly associated with reduced DFS and OS (DFS:HR = 2.4, p = 0.001; OS:HR = 1.9, p = 0.028).
Conclusion
In this select cohort of PDAC patients with optimal NAT response, pre‐NAT CA19‐9 ≥ 400U/mL is strongly associated with decreased DFS and OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
- Department of Surgery, University of Texas Southwestern, Dallas, TX, USA.
- Department of Surgery, NorthShore University Health System, Evanston, IL, USA.
- Department of Surgery, West Virginia University, Morgantown, WV, USA.
- Department of Surgery, Erasmus Medical Center, Rotterdam, Netherlands.
ORCID-Profile: Anthony Gebran, Carl Schmidt, Alessandro Paniccia
Zitieren
APA
Gebran, A., Chopra, A., Farah, E., Hays, S., Ranson, K., Rojas, A., Ceuppens, S., Schmitz, R., Liu, H., Tirukkovalur, N. V., Talamonti, M., Lee, K. K., Zeh, H. J., Schmidt, C., Boone, B. A., Hogg, M., Zureikat, A. H., Polanco, P. M., & Paniccia, A. (2026). Pretreatment CA19‐9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70179
Vancouver
Gebran A, Chopra A, Farah E, Hays S, Ranson K, Rojas A, et al. Pretreatment CA19‐9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy. Journal of Surgical Oncology. 2026. doi:10.1002/jso.70179
BibTeX
@article{Gebran2026,
author = {Gebran, Anthony and Chopra, Asmita and Farah, Emile and Hays, Sarah and Ranson, Kristen and Rojas, Aram and Ceuppens, Sebastiaan and Schmitz, Robin and Liu, Hao and Tirukkovalur, Nikhil V and Talamonti, Mark and Lee, Kenneth K and Zeh, Herbert J and Schmidt, Carl and Boone, Brian A and Hogg, Melissa and Zureikat, Amer H and Polanco, Patricio M and Paniccia, Alessandro},
title = {Pretreatment CA19‐9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy},
journal = {Journal of Surgical Oncology},
year = {2026},
doi = {10.1002/jso.70179}
}
EUVIMED